与背景种群相比，从胃腺癌治愈的患者中生存
Survival among patients cured from gastric adenocarcinoma compared to the background population
影响因子:5.10000
分区:医学2区 / 胃肠肝病学2区 肿瘤学2区
发表日期:2024 Nov
作者:
Wilhelm Leijonmarck, Fredrik Mattsson, Jesper Lagergren
摘要
与背景人群相比，胃腺癌幸存者的生存期是否更长，更短或类似的生存期是尚不清楚的。这些知识可能有助于基于证据的监测策略，医疗保健建议和患者和家庭的信息。这项基于人群的同类研究包括所有在2006 - 2015年间在瑞典的胃腺癌进行胃切除术的患者，并在手术后5年存活。随访直到死亡，术后10年或学习期结束（2020年12月31日）。预期存活率观察到的分裂使用救生表方法以95％的置信区间（CI）产生了相对存活率。预期的生存来自相应年龄，性别和日历年的整个瑞典人口。数据来自医疗记录和全国登记册。所有767个胃腺癌幸存者的生存比预期的要短。 The reduction in relative survival increased for each follow-up year, from 97.3% (95% CI 95.4-99.1%) year 6 to 86.6% (95% CI 82.3-90.9%) year 10. The decline in relative survival was more pronounced among patients who had gastrectomy in earlier calendar years (82.9% [95% CI 77.4-88.4%] year 10 for years 2011-2015），较短的教育（85.2％[95％CI 77.4-93.0％]教育10年≤9岁），更多的合并症（78.0％[95％CI 63.9-92.0％] Charlson合并症得分效应10≥2），没有NeoAdadJuvant疗法（83.2％）（83.2％）[95％] 10）。胃腺癌幸存者的存活率似乎比相应的背景人群较差，尤其是在某些亚组中。
Abstract
It is unknown if gastric adenocarcinoma survivors have longer, shorter, or similar survival compared to the background population. This knowledge could contribute to evidence-based monitoring strategies, healthcare recommendations, and information for patients and families.This population-based cohort study included all patients who underwent gastrectomy for gastric adenocarcinoma between 2006-2015 in Sweden and survived ≥ 5 years after surgery. They were followed up until death, postoperative year 10, or end of study period (31 December, 2020). Division of the observed by the expected survival yielded relative survival rates with 95% confidence intervals (CIs) using the life table method. The expected survival was derived from the entire Swedish population of the corresponding age, sex, and calendar year. Data came from medical records and nationwide registers.The survival among all 767 gastric adenocarcinoma survivors was shorter than the expected. The reduction in relative survival increased for each follow-up year, from 97.3% (95% CI 95.4-99.1%) year 6 to 86.6% (95% CI 82.3-90.9%) year 10. The decline in relative survival was more pronounced among patients who had gastrectomy in earlier calendar years (82.9% [95% CI 77.4-88.4%] year 10 for years 2011-2015), shorter education (85.2% [95% CI 77.4-93.0%] year 10 for education ≤ 9 years), more comorbidities (78.0% [95% CI 63.9-92.0%] year 10 for Charlson comorbidity score ≥ 2), and no neoadjuvant therapy (83.2% [95% CI 77.4-89.0%] year 10).Gastric adenocarcinoma survivors seem to have poorer survival than the corresponding background population, particularly in certain subgroups.